Full Text View
Tabular View
No Study Results Posted
Related Studies
An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)
This study has been completed.
First Received: November 2, 1999   Last Updated: June 23, 2005   History of Changes
Sponsored by: Pfizer
Information provided by: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier: NCT00002090
  Purpose

To evaluate the efficacy and safety of two doses of azithromycin given chronically for the treatment of Mycobacterium avium bacteremia in AIDS patients.


Condition Intervention
Mycobacterium Avium-Intracellulare Infection
HIV Infections
Drug: Azithromycin

Study Type: Interventional
Study Design: Treatment, Dose Comparison, Safety Study
Official Title: An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)

Resource links provided by NLM:

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Medications allowed under a Treatment IND program.

Patients must have:

  • HIV infection.
  • Disseminated Mycobacterium avium Complex.
  • Fever (> 100 degrees F) that cannot be attributed to another active infection, and at least one other constitutional symptom (such as fatigue, malaise, anorexia).
  • Life expectancy of at least the duration of the study.
  • Consent of parent or guardian if below the legal age of consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

  • Known hypersensitivity or significant intolerance to macrolide antibiotics.
  • Inability to take oral medications or a current condition likely to interfere with drug absorption (e.g., gastrectomy).

Prior Medication:

Excluded:

  • Treatment with an immunostimulant or immunomodulator compound such as alpha-interferon, gamma-interferon, or any interleukin within 7 days prior to study entry.
  • Any other antibiotic with known activity against M. avium within 7 days prior to study entry.

Not expected to comply with the requirements of the protocol, in the opinion of the investigator.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002090

Locations
United States, Massachusetts
Beth Israel Hosp
Boston, Massachusetts, United States, 02215
United States, New York
SUNY / Health Sciences Ctr at Syracuse
Syracuse, New York, United States, 13210
Bronx Veterans Affairs Med Ctr
Bronx, New York, United States, 10468
United States, Ohio
Ohio State Univ Hosp
Columbus, Ohio, United States, 43210
United States, Texas
United States Air Force Med Ctr
Lackland Air Force Base, Texas, United States, 78236
Audie L Murphy Veterans Administration Hosp
San Antonio, Texas, United States, 78284
Sponsors and Collaborators
Pfizer
  More Information

No publications provided

Study ID Numbers: 058H, 066-148
Study First Received: November 2, 1999
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00002090     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
Mycobacterium avium-intracellulare Infection
Acquired Immunodeficiency Syndrome
Azithromycin

Study placed in the following topic categories:
Bacterial Infections
Anti-Infective Agents
Sexually Transmitted Diseases, Viral
Acquired Immunodeficiency Syndrome
Immunologic Deficiency Syndromes
Mycobacterium Infections, Atypical
Mycobacterium Avium Complex Infection
Mycobacterium avium-intracellulare Infection
Virus Diseases
Anti-Bacterial Agents
Gram-Positive Bacterial Infections
HIV Infections
Azithromycin
Sexually Transmitted Diseases
Mycobacterium Infections
Retroviridae Infections

Additional relevant MeSH terms:
Bacterial Infections
Communicable Diseases
Anti-Infective Agents
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Infection
Anti-Bacterial Agents
Gram-Positive Bacterial Infections
Pathologic Processes
Therapeutic Uses
Syndrome
Azithromycin
Retroviridae Infections
RNA Virus Infections
Disease
Immune System Diseases
Acquired Immunodeficiency Syndrome
Pharmacologic Actions
Immunologic Deficiency Syndromes
Actinomycetales Infections
Mycobacterium Infections, Atypical
Mycobacterium avium-intracellulare Infection
Virus Diseases
HIV Infections
Sexually Transmitted Diseases
Lentivirus Infections
Mycobacterium Infections

ClinicalTrials.gov processed this record on September 01, 2009